With support from the Victorian State Government, PI and Lumos will establish a $17.2 million Rapid Diagnostics Manufacturing Facility and Innovation Hub in Victoria to locally manufacture RATs.
When developing connectivity for your point-of-care diagnostic product, there are two main routes – build or buy. How do you know what’s right for you?
Planet Innovation is taking another step in providing a safe working environment for on-site staff by introducing voluntary COVID-19 rapid antigen testing at its Australian facility.
As demand for diagnostic and point-of-care (POC) testing grows, new products are coming to life faster than ever. Ben Druce, VP Strategic Design, shares insights from an expert panel discussion he hosted at the MD&M and BIOMEDigital event.
Experts from Truvian, Blue Ox Healthcare Partners, the University of Chicago and PI discuss the potential impact of real-time point-of-care blood testing.
With the COVID-19 pandemic shining a light on the benefits of telehealth, there has never been a better time to be in remote patient monitoring (RPM). But if you’re going to be successful, you need to win over your two main users: patients and clinicians.
Lumos Diagnostics, a rapid point-of-care diagnostics company spun out of Planet Innovation, has closed an oversubscribed AU$25 million pre-IPO capital raise, ahead of an anticipated 2021 Australian Securities Exchange (ASX) listing.
Planet Innovation and Lumos Diagnostics have won two awards at the 2020 Good Design Awards, including a Good Design Award Gold accolade for Lumos’s Leelu Reader.
A roundup of the latest news and opinions from PI.
PI has partnered with Truvian, a healthcare company at the intersection of diagnostics and consumer technology, to develop a new point-of-care blood testing device to make routine health tests more convenient, affordable and actionable for consumers.
We are seeking GPs and other healthcare professionals in Victoria, Australia to pilot a new TGA-approved point-of-care test to help differentiate patients with viral from bacterial acute respiratory tract infections.
Lumos Diagnostics and RPS Diagnostics have merged to create a full-service point-of-care diagnostic development company and support the international commercialization of FebriDx.
Lumos Diagnostics is expanding its global footprint after agreeing an ongoing manufacturing deal for a customized lateral flow reader with a California-based life sciences company.
Lumos Diagnostics develops custom products for its partners using a unique combination of integrated assay and engineering capability paired with its proven reader optical technologies.
Planet Innovation’s PoC (Point-of-Care) diagnostic platform, Nplex, will benefit from further investment to develop a cloud-connected medical counter-measures device, for the rapid detection of infectious diseases.